These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36998294)

  • 1. The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma.
    Matsumura M; Honda G; Tani K; Nemoto S; Ome Y; Hayakawa S; Suzuki M; Horiguchi SI; Kikuyama M; Seyama Y
    Ann Gastroenterol Surg; 2023 Mar; 7(2):306-317. PubMed ID: 36998294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
    Suto H; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Kumamoto K; Suzuki Y; Okano K
    HPB (Oxford); 2023 Jan; 25(1):136-145. PubMed ID: 36307256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
    Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis.
    Oba A; Wu YHA; Colborn KL; Karam SD; Meguid C; Al-Musawi MH; Bao QR; Gleisner AL; Ahrendt S; Schulick RD; Del Chiaro M
    Br J Surg; 2022 Apr; 109(5):450-454. PubMed ID: 35136963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada YU; Kumamoto T; Endo I
    Anticancer Res; 2019 Aug; 39(8):4431-4440. PubMed ID: 31366541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between postoperative recurrences and standardized uptake value on
    Suto H; Nagao M; Matsukawa H; Fuke T; Ando Y; Oshima M; Takahashi S; Shibata T; Kamada H; Kobara H; Okuyama H; Hirao T; Kumamoto K; Okano K
    Pancreatology; 2024 Nov; 24(7):1133-1140. PubMed ID: 39160121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
    Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
    Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
    World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.